Peptide Science
Selank and Semax: intriguing brain research, no canine answers yet
The evidence is much thinner than the online conversation suggests.
Selank and Semax are synthetic regulatory peptides developed in a narrow research tradition. Selank is related to tuftsin; Semax is derived from a fragment of adrenocorticotropic hormone.
They are discussed online for cognitive decline, anxiety, and reactivity in dogs. We found no controlled canine studies supporting those uses and no canine pharmacokinetic or safety work.
How they may work
Rodent research examines changes in stress behaviour, inflammatory signalling, neurotransmitter systems, gene expression, and responses to experimental brain injury.
These are broad biological signals. They do not demonstrate that either peptide improves anxiety, reactivity, or cognitive decline in a pet dog.
Why they are discussed for dogs
Age-related confusion, disrupted sleep, anxiety, and changed responses to familiar situations are emotionally difficult for families. That creates understandable interest in anything described as neuroprotective or calming.
The thinner the evidence base, the more important it is not to turn that interest into a treatment claim.
What the evidence can support
Selank has been studied in rats under stress and drug-withdrawal models. Semax has been studied in rodent stress, ischemia, and neural-signalling models.
Those experiments support continued laboratory investigation. They do not establish canine effectiveness or safety.
What would need to be studied in dogs
Identity and pharmacokinetics first, followed by tolerability and carefully defined behavioural or cognitive endpoints.
Trials would need to distinguish cognitive dysfunction, fear, pain-related behaviour, sleep disruption, and reactivity rather than treating them as one problem.
Actual studies
- Rat behavioral modelPubMed PMID 36322304
Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
Konstantinopolsky MA, Chernyakova IV, Kolik LG. Bulletin of Experimental Biology and Medicine. 2022;174(1):68–72.
- Study design
- Controlled experimental study of withdrawal-associated behavior in rats.
- Population
- Laboratory rats; no dogs were studied.
- Intervention
- Selank in an experimentally induced morphine-withdrawal model.
- What was measured
- Behavioral signs associated with withdrawal.
- What the paper reported
- The authors reported attenuation of selected aversive behavioral signs in treated rats.
- Important limitations
- A narrow rodent model unrelated to canine cognitive decline or ordinary anxiety. It cannot establish a canine treatment effect.
- Rat chronic-stress modelPubMed PMID 39442746
Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress
Inozemtseva LS, Yatsenko KA, Glazova NY, et al. European Journal of Pharmacology. 2024;984:177068.
- Study design
- Controlled preclinical study using chronic unpredictable stress.
- Population
- Male rats; no dogs were studied.
- Intervention
- Semax or comparator peptide during an experimental stress protocol.
- What was measured
- Behavioral and stress-related outcomes in the model.
- What the paper reported
- The authors reported antidepressant-like and antistress effects in treated rats.
- Important limitations
- Rodent behavior under induced stress cannot establish benefit for canine anxiety, reactivity, or cognitive dysfunction.
Keep reading
BPC-157
ReadCanine preclinical researchSS-31 / Elamipretide
ReadCanine clinical researchBioactive collagen peptides
ReadAnimal / mechanistic researchThymosin Beta-4
ReadDirect canine researchGHK-Cu
ReadAnimal / mechanistic researchKPV
ReadAnimal / mechanistic researchMOTS-c
ReadEmerging researchThymosin Alpha-1
Read